IGF1R and melanoma: HAT1 downregulation is associated with non-responsiveness of BRAFi and MEKi in melanoma patients, and HAT1 depletion drives resistance to BRAFi vemurafenib and dabrafenib by upregulating MAPK via IGF1R in melanoma cells 96.